Cancer Network interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Jonathan Ledermann, MD
Advertisement
Articles by Jonathan Ledermann, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
3
Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist
4
ASCENT-03: Sacituzumab Govitecan Versus Chemotherapy in First-Line Metastatic TNBC
5